MedTrace Logo

Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6

NCT01433887 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 535

Last updated 2014-11-18

No results posted yet for this study

Summary

The Chinese patients with chronic hepatitis C have a different genetic background, which had been demonstrated to significantly influence their responses to pegylated interferon and ribavirin. In this study, Chinese patients with Hepatitis C Virus genotype 1, 2/3, 6 infection were treated with pegylated interferon and ribavirin. Their response was compared amongst different genotypes.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

48-weeks course

patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks

DRUG

Ribavirin

patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks

DRUG

Peginterferon alfa2a

patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks

DRUG

Ribavirin

patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks

Sponsors & Collaborators

  • Third Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01433887 on ClinicalTrials.gov